Aller au contenu principal
Accès ouvert déclaré 2026 article

Identification of prognostic biomarkers in a large cohort of patients with LGMD R2

0Citations signalées, ce qui n’est pas une note de qualité
29Institutions déclarées
9Pays d’affiliation déclarés

Rattachement africain : gb, us, fr, be, de, au, es, jp, it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Limb-girdle muscular dystrophy R2-dysferlin related (LGMD-R2) is a progressive muscle condition with marked variability in disease course, making prognosis challenging. Quantitative MRI (qMRI) has emerged as a complementary tool that may detect progression earlier and more precisely. Integrating different data modalities is challenging with conventional approaches, and artificial intelligence (AI) can help overcome this. Our aim is to develop robust models capable of predicting clinical progression in LGMD-R2 by incorporating AI-based techniques into the analysis pipeline. METHODS: Data from 188 COS 1 participants were analysed. Disease progression was assessed using the North Star Assessment for Limb Girdle type Muscular Dystrophies (NSAD). Ambulatory individuals with a maximum NSAD ≥ 20 were included, and progression trajectories were identified through hierarchical clustering. Feature selection was performed using a machine learning pipeline, and top predictors were entered into stepwise logistic regression to build clinical-only and combined clinical-MRI models. RESULTS: Two stages of progression were identified, a fast one with a mean three-year loss of 14.4 NSAD points, and a moderate one, with a mean loss of 3.8 NSAD points. The combined model achieved better balanced accuracy than the clinical-only one (83.7% vs 78.7%). Key predictors in the combined model were disease duration and fat content measures in the anterior thigh and gracilis muscle, while the clinical model included disease duration, creatine phosphokinase (CK), and 10 m walk/run test velocity. CONCLUSIONS: Progression in LGMD-R2 can be grouped into distinct clinical trajectories. Individuals at a faster stage of progression were younger, had shorter disease duration, higher CK, greater weakness, and relatively preserved vastus intermedius and gracilis muscles. AI enabled efficient integration of heterogeneous data, and qMRI biomarkers provided complementary information that improved predictive accuracy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Identification of prognostic biomarkers in a large cohort of patients with LGMD R2
Date Crossref
26/05/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Muscle Physiology and DisordersNutrition and Health in AgingGenetic Neurodegenerative Diseases

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.